查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1944262

慢性阻塞性肺病（COPD）治疗全球市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

慢性阻塞性肺病(COPD) 治疗市场规模预计将从 2025 年的 293.1 亿美元增长到 2034 年的 455.5 亿美元，2026 年至 2034 年的复合年增长率为 5.02%。

随着慢性阻塞性肺病（COPD）在全球盛行率持续上升，COPD治疗市场预计将迎来显着成长。 COPD是一种进行性肺部疾病，其特征是气流受限，导致呼吸困难和生活品质下降。吸烟、空气污染和职业暴露等风险因素的增加，推动了对有效COPD治疗药物的需求，包括支气管扩张剂、皮质类固醇和联合治疗。随着医疗机构寻求改善患者预后和控制症状，COPD治疗市场预计将进一步扩大。

技术创新在塑造慢性阻塞性肺病（COPD）治疗市场的未来方面发挥关键作用。吸入器和雾化器等药物输送系统的创新正在提高COPD治疗的有效性和便利性。此外，包括行动应用程式和远端监测设备在内的数位健康技术的整合，正在帮助患者更有效地管理病情。随着製造商持续加大研发投入，预计COPD治疗市场将在各种医疗机构中更广泛地采用创新解决方案。

此外，对病患教育和自我管理的日益重视正在推动慢性阻塞性肺病（COPD）治疗市场的成长。随着患者对自身病情和治疗方案的了解不断加深，他们对有效自我管理所需的资源和支持系统的需求也日益增长。这一趋势促使医疗服务提供者、製药公司和患者权益组织合作，共同开发教育项目，主导患者掌控自身健康。随着市场的不断发展，技术整合、患者参与和个人化护理将成为成功的关键驱动因素。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 绘製渗透率和成长前景图
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制
    • 市场机会
    • 市场问题
  • 波特五力分析
  • PESTLE分析

4. 全球慢性阻塞性肺病(COPD) 治疗市场（依药物类别划分）

  • 市场分析、洞察与预测
  • 联合治疗
  • 支气管扩张剂
  • 皮质类固醇
  • 磷酸二酯酶4型抑制剂
  • 黏液动力学
  • 其他的

5. 全球慢性阻塞性肺病(COPD) 治疗市场（按类型划分）

  • 市场分析、洞察与预测
  • 慢性支气管炎
  • 气肿

6. 全球慢性阻塞性肺病(COPD) 治疗市场（依分销管道划分）

  • 市场分析、洞察与预测
  • 医院药房
  • 零售药房
  • 网路药房

7. 全球慢性阻塞性肺病（COPD）治疗市场（按地区划分）

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商格局（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Almirall
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • CHIESI Farmaceutici SP A
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKiine Plc
    • Kyowa Hakko Kirin
    • Mylan NV
    • Novartis AG
    • Orion Corporation
    • Sanofi
    • Sunovion Pharmaceuticals Inc.（Sumitomo Dainippon Pharma Co. Ltd）
    • Teva Pharmaceutical Industries Ltd
    • Theravance Biopharma
    • Verona Pharmaceuticals
简介目录
Product Code: VMR11218849

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size is expected to reach USD 45.55 Billion in 2034 from USD 29.31 Billion (2025) growing at a CAGR of 5.02% during 2026-2034.

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is poised for significant growth as the prevalence of COPD continues to rise globally. COPD is a progressive lung disease characterized by airflow limitation, leading to breathing difficulties and reduced quality of life. The increasing incidence of risk factors such as smoking, air pollution, and occupational exposures is driving the demand for effective COPD treatments, including bronchodilators, corticosteroids, and combination therapies. As healthcare providers seek to improve patient outcomes and manage symptoms, the market for COPD treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the COPD treatment market. Innovations in drug delivery systems, such as inhalers and nebulizers, are enhancing the efficacy and convenience of COPD therapies. Additionally, the integration of digital health technologies, including mobile applications and remote monitoring devices, is empowering patients to manage their condition more effectively. As manufacturers continue to invest in research and development, the COPD treatment market is likely to see increased adoption of innovative solutions across various healthcare settings.

Moreover, the growing emphasis on patient education and self-management is influencing the COPD treatment market's growth trajectory. As patients become more informed about their condition and treatment options, there is a rising demand for resources and support systems that facilitate effective self-management. This trend is driving collaboration between healthcare providers, pharmaceutical companies, and patient advocacy groups to develop educational initiatives that empower patients to take control of their health. As the market continues to evolve, the integration of technology, patient engagement, and personalized care will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici Sp A, F HoffmannLa Roche Ltd, GlaxoSmithKiine plc, Kyowa Hakko Kirin, Mylan NV, Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd, Teva Pharmaceutical Industries Ltd, Theravance Biopharma, Verona Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Combination Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Phosphodiesterase Type 4 Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Mucokinetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Chronic Bronchitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Emphysema Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drug Class
    • 7.2.2 By Type
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drug Class
    • 7.3.2 By Type
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drug Class
    • 7.4.2 By Type
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drug Class
    • 7.5.2 By Type
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drug Class
    • 7.6.2 By Type
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Almirall
    • 9.2.2 AstraZeneca
    • 9.2.3 Boehringer Ingelheim International GmbH
    • 9.2.4 CHIESI Farmaceutici S.P A
    • 9.2.5 F. Hoffmann-La Roche Ltd
    • 9.2.6 GlaxoSmithKiine Plc
    • 9.2.7 Kyowa Hakko Kirin
    • 9.2.8 Mylan NV
    • 9.2.9 Novartis AG
    • 9.2.10 Orion Corporation
    • 9.2.11 Sanofi
    • 9.2.12 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
    • 9.2.13 Teva Pharmaceutical Industries Ltd
    • 9.2.14 Theravance Biopharma
    • 9.2.15 Verona Pharmaceuticals